0.6800USD-1.08%Mkt Cap: 7.50M USDP/E: —Last update: 2026-05-22
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn propriet…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap7.50M USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.31M USD
Revenue/Share—
Last Price0.6800 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS10501E2019
Valuation
P/E (Trailing)—
P/E (Forward)-0.83
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.78
EPS (TTM)-0.85
EPS (Forward)-0.86
52W Range
0.460025% of range1.330
52W High1.330 USD
52W Low0.4600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE103.22%
ROA-1008.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.97M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.02
Current Ratio—
Quick Ratio—
Book Value/Sh-0.9050 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateOct 1, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.11.03M
Float—
Insiders9.08%
Institutions0.00%
Short Interest
Short Ratio1.3d
Short % Float6.46%
Short % Out.5.97%
Shares Short604.46K
Short (prev mo.)536.94K
Technical
SMA 500.7958 (-14.6%)
SMA 2000.6807 (-0.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)9.20K
Avg Vol (10d)10.21K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—